title: Prime time for molecular marker diagnostics in neuro-oncology.
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
authors.forename: Roger
authors.initials: R
authors.lastname: Stupp
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D003131:Combined Modality Therapy; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D006801:Humans; D011379:Prognosis; D011401:Promoter Regions, Genetic; D011878:Radiotherapy; D016032:Randomized Controlled Trials as Topic; D000077204:Temozolomide; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide